Oral curcumin or curcuminoid supplementation across mixed formulations × Reduction of LDL cholesterol in adults with dyslipidemia or metabolic disease

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich LDL question is addressed?Required	The original claim concerns LDL-C reduction in adults with dyslipidemia or metabolic disease. HDL, TG and total cholesterol are separate outcomes. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease	Material needed: Original eligibility criteria matching population, formulation, comparator and LDL are needed. Other lipids, myocardial infarction and medicine replacement are excluded. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre mixed formulations distinguished from individual products?Required	The retained formulation mixes conventional, nano and phytosomal oral products. Other formulations, piperine combinations and topical products are not treated as equivalent. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original-trial composition by conventional, nano and phytosomal formulations	Material needed: Active amounts, absorption enhancers and product information are needed. A mixed estimate does not establish efficacy or equivalence for an individual formulation. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhat doses and actual exposure are recorded?Required	Doses vary by trial. Representative doses, active-amount conversions and recommended amounts are not generated. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Total product and active-curcuminoid amounts, frequency and adherence	Material needed: Original trial records on formulation, dose, co-ingredients and adherence are needed. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionAre treatment duration and LDL measurement timepoints aligned?Required	The retained duration varies from weeks to months. It is not merged into a single fixed timepoint or persistent effect. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific durations and LDL timepoints over weeks to months	Material needed: Treatment, measurement, end-of-follow-up and post-discontinuation timepoints, with selection rules, are needed. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionWhich diagnoses make up the mixed adult population?Required	The retained population mixes adults with these diagnoses. It is not presented as a single dyslipidemia population. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL	Material needed: Inclusion tables by diagnosis, baseline LDL, age, comorbidities and eligibility are needed. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionHow does the T2D analysis relate to the broader analysis?Required	R02 is a T2D RCT meta-analysis, while R01 mixes diseases and formulations. Two review reports are not counted as two independent original trials. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Alignment of T2D eligibility with mixed-disease and formulation scopes	Material needed: Alignment of diseases, formulations and timepoints, with original-trial lists shared by the reviews, is needed. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionHow do comparator arrangements differ?Required	The retained comparator is placebo or control care. Identical placebo and lifestyle-management arrangements across all trials are not established. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Placebo or control care and common management in each group	Material needed: Original-trial records on comparator ingredients, blinding, diet/exercise management and added interventions are needed. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionCan lipid and glucose medicines be separated from other interventions?Required	The original precaution says not to stop lipid medicines without appropriate guidance. Medicine types, maintenance and changes in included trials are not detailed in the summary. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Group-specific lipid/glucose medicines, diet and weight changes	Material needed: Baseline medicines, treatment changes, adherence and shared care are needed. Curcumin alone or a statin-replacement comparison is not established. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionAre each review's design and eligibility scope retained separately?Required	R01 is a systematic review/meta-analysis of RCTs; R02 is a T2D RCT meta-analysis. Disease and formulation scopes differ. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Search and eligibility criteria for the updated RCT review and T2D RCT review	Material needed: Search dates, strategies, eligibility, registration/plans and extraction tables are needed for each review. Currentness and directness are not newly certified. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionAre the numbers of included trials known?Required	R01 describes multiple RCTs with mixed diseases/formulations; R02 describes pooled T2D RCTs. Specific RCT counts are not provided. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Included RCT counts and study/report links for each review	Material needed: Inclusion lists, multiple-arm arrangements and duplicate-report links are needed. Unique-trial counts are not generated. This records needed materials; no new research was executed.
11	Unverified	Full text not readStored summary read	N11 · Evidence conditionAre participants and analysis denominators known?Required	The stored sample descriptions contain no participant totals or group counts. Generic English wording does not supply actual denominators. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial/group denominators for allocation, analysis, completion and LDL measurement	Material needed: Allocation, analysis, completion and measurement denominators, with participant-overlap information, are needed. The final unique-participant total remains null. This records needed materials; no new research was executed.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionCan trials shared by the reviews be linked?Required	The two structured reports are the Saeedi and Yuan reviews. Overlap in original trials and participants remains unverified. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Review-to-original-trial, additional-report and shared-participant links	Material needed: Article, registration, site/time and sample links are needed. Review estimates are not added or certified as two independent replications. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionWhat is the LDL result in the broader updated analysis?Required	R01 reports SMD −0.17, 95% CI −0.43 to 0.09, P=.20. Its retained interpretation describes the latest direct LDL synthesis as null. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	R01 SMD, CI and P, with original model and scale	Material needed: Original pooling tables, standardization, variances, weights, included-trial and timepoint extraction are needed. New values are not calculated. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionWhat is the LDL result in the T2D analysis?Required	R02 reports MD −4.01 mg/dL, 95% CI −10.96 to 2.95, P=.259, described as null. R01's SMD is not copied to this report. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	R02 MD in mg/dL, CI and P, with the original analysis population	Material needed: T2D included trials, formulations, timepoints, variances/denominators and analysis models are needed. This records needed materials; no new research was executed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionAre SMD and MD in mg/dL kept without conversion?Required	R01 uses SMD; R02 uses MD in mg/dL. They are not compared, added or converted, and remain within their respective disease/formulation scopes. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Units and estimands for standardized and absolute differences	Material needed: Original standard deviations, analysis arrangements and direct comparisons addressing the same question are needed. No SMD-to-mg/dL conversion or new pooled estimate is produced. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionAre intervals crossing no effect distinguished from equivalence?Required	The original CIs are −0.43 to 0.09 and −10.96 to 2.95. The original interpretation as null is retained. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Both original CIs and P values, with prespecified importance/equivalence criteria	Material needed: Original analysis tables and prespecified importance/equivalence criteria are needed. Lack of significance does not certify effect 0 or equivalence for every formulation. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionWhich report underlies the roughly 6–10 mg/dL positive signal?Supplementary	The counterview mentions roughly 6–10 mg/dL lower LDL in some metabolic-disease analyses. Structured R02 instead reports −4.01 mg/dL, described as null. The positive narrative is not assigned to R02. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Bibliography, formulations, denominators and CIs for earlier positive analyses	Material needed: Articles/years, original trials and direct LDL tables for the positive analyses are needed. Unidentified reports, effects and CIs are not invented. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionAre the 2013–2025 narrative and citation years distinguished?Required	The research narrative mentions comparisons of meta-analyses from 2013–2025. Both structured citations have 2022 bibliographies. These different original records are retained. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Review chronology, search end dates, versions and bibliography alignment	Material needed: Report lists, versions, search dates and original citations for the stated years are needed. No new 2025 paper or completed external current search is created. This records needed materials; no new research was executed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionWhat explains differences and heterogeneity across analyses?Required	The original narrative describes earlier positive/null findings and conclusions varying by disease/formulation. The result fields contain no I² value. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Heterogeneity and sensitivity analyses by disease, formulation, duration and model	Material needed: Original heterogeneity, sensitivity/classification and extraction tables are needed. Different review scopes are not established as conflicting results from identical original trials; I² and prediction intervals are not invented. This records needed materials; no new research was executed.
20	Unverified	Full text not readStored summary read	N20 · Evidence conditionWhat is known about original-trial allocation, blinding and risk assessment?Required	The RCT-review design is retained. Original-trial methods and individual risk-assessment material were not externally read in this work. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original allocation, concealment, blinding/measurement methods and assessment bases	Material needed: Original methods, registration/plans and review-level individual assessment bases are needed. Official RoB2/GRADE findings are not generated. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionAre LDL measurement, change and adjustment arrangements comparable?Required	The selected endpoint is blood LDL-C change. Original assays, final/change-value definitions and adjustment arrangements are not detailed in the summary. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Assays, fasting, final/change values, baseline adjustment and estimands	Material needed: Assays, timepoints, extraction tables, variance handling and analysis plans are needed. This records needed materials; no new research was executed.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionWhat attrition, missingness and analysis exclusions are known?Required	Stored sample descriptions provide no specific denominators. Unread original trials are not relabeled as having no missingness or withdrawals. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial-specific missing measurements, withdrawals and analysis sets	Material needed: Group-specific flow diagrams, missingness, exclusion reasons, missing-data handling and sensitivity material are needed. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionAre LDL prespecification and reporting choices verified?Required	An LDL-only verdict does not mean that every original trial prespecified LDL as its primary (1st) endpoint. Prespecified hierarchy remains unverified. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Primary/secondary endpoints, timepoints and multiplicity plans	Material needed: Registration, protocols/SAPs and all-timepoint result tables are needed. This records needed materials; no new research was executed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionAre disease/formulation subgroups kept separate from overall effects?Supplementary	The original rationale retains the latest direct null LDL result, while the counterview retains positive signals in restricted metabolic-disease analyses. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Subgroup effects/CIs, denominators, prespecification and interactions	Material needed: Subgroup tables, interactions and distinctions by formulation/duration are needed. The overall SMD is not copied as a disease-specific or product-specific estimate. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionAre other lipid endpoints distinguished from LDL benefit?Supplementary	The summary states that these lipids are separate outcomes, and the rationale/advertising limits do not transfer positive TG or total-cholesterol findings to LDL. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Outcome-specific definitions and results for HDL, TG and total cholesterol	Material needed: Original results for other lipids address separate questions. Effects and grades are not merged into the LDL table. This records needed materials; no new research was executed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionAre statin replacement and myocardial-infarction prevention separate questions?Supplementary	The retained advertising limits do not support statin replacement or myocardial-infarction prevention. The current endpoint is LDL-C. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Direct material distinguishing an LDL surrogate from medicine replacement and clinical events	Material needed: Direct comparisons on medicine replacement or cardiovascular events are not verified in this material. Efficacy scope is not expanded. This records needed materials; no new research was executed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionAre replication within a formulation and optimum doses verified?Supplementary	The original grading rationale describes conflicting syntheses and a null latest direct main effect. Mixed reviews do not establish formulation-specific replication or optimum doses. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Unique trials, independent teams and direct dose comparisons	Material needed: Direct material on original-trial families, products, teams, doses and timepoints is needed. This records needed materials; no new research was executed.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionAre four routes of company involvement distinguished?Required	R01 describes university researchers and mixed funding of included trials; R02 describes limited verification. Generic English funding wording does not complete these four records. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Report/trial-specific funding, product support, employee authorship and COI	Material needed: Original support, product-provision, affiliation and COI disclosures for reviews/trials are needed. University researchers do not establish absence of company involvement. This records needed materials; no new research was executed.
29	Unverified	Full text not readStored summary read	N29 · Evidence conditionAre harm collection methods and event tables known?Supplementary	The original safety detail retains these precautions separately from efficacy. Collection methods and event tables are not preserved in detail. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events	Material needed: Harm methods, severity, occurrence and discontinuation records are needed. Precautions do not establish incidence, causation or safety certification. This records needed materials; no new research was executed.
30	Unverified	Full text not readStored summary read	N30 · Evidence conditionAre harm denominators and exposure kept distinct?Supplementary	Sample descriptions express review scopes without participant counts. Durations are mixed too. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Safety populations, dosing, duration, event counts and comparators	Material needed: Group-specific safety sets, exposure amounts/time, withdrawals and comparator events are needed. Harm incidence is not calculated or replaced with LDL denominators. This records needed materials; no new research was executed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionAre alternative causes and concomitant treatments separated for harms?Supplementary	The original record cautions against stopping lipid medicines without appropriate guidance and retains curcumin precautions separately. Event and co-treatment causation remains unverified. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Comorbidities, medicines, event timing and alternative causes	Material needed: Medicine maintenance/changes, baseline disease, event timing, comparators and post-discontinuation course are needed. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionDoes a bleeding precaution establish a direct interaction result?Supplementary	A bleeding precaution is retained, but medicine-specific incidence and interaction comparisons are not specified. Medicine-specific causal claims are not added here. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing a bleeding precaution from medicine-specific direct comparisons	Material needed: Concomitant medicine types, exposure, group-specific events, alternative causes and direct comparisons are needed. This records needed materials; no new research was executed.
33	Unverified	Full text not readStored summary read	N33 · Evidence conditionAre long-term, hepatobiliary and vulnerable-population harms verified?Supplementary	Hepatobiliary precautions remain separate from efficacy. Mixed durations of weeks to months do not certify long-term safety. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure	Material needed: Long-term follow-up, independent harm reports, vulnerable-population, exposure/denominator and causal material are needed. No new harm investigation is undertaken. This records needed materials; no new research was executed.
34	Partly verified	Full text not readStored summary read	N34 · Evidence conditionAre stored-summary reading and external original links distinguished?Required	The stored summary and bibliography were read. The two PubMed URLs are original links. External abstracts, full texts, registration and protocols/SAPs remain unread. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs	Material needed: Unread status remains until actual materials are acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions. This records needed materials; no new research was executed.
35	Partly verified	Full text not readStored summary read	N35 · Evidence conditionHow are generic English wording and the historical correction retained?Supplementary	The correction records replacement of English placeholders while retaining grade, score, citations and evidence date. Remaining generic English denominator, result and funding wording is preserved in the original record. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original Korean/English records and limits of the 2026-09-14 correction	Material needed: External English material and historical correction targets are not newly reviewed here. The historical correction is not labeled as completed current QA. This records needed materials; no new research was executed.
36	Partly verified	Full text not readStored summary read	N36 · Evidence conditionAre original grade, axes, dates and preparation distinguished?Required	The original D/30/Caution, evidence date 2026-09-08, axes and correction are retained. This is not a new efficacy grade or independent verification. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Preservation of D30, Caution, axes, evidence date and correction	Material needed: New material, changed conditions and changed verdicts are recorded as separate events after appropriate review. The original date is not reused as a current search or external-reading date. This records needed materials; no new research was executed.

No items match your search or filter.

36 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-08
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Population: The retained population mixes adults with dyslipidemia, type 2 diabetes, metabolic syndrome and related conditions. Disease, baseline LDL, eligibility, age-specific direct effects and contributing denominators remain incompletely verified.
Ingredient, formulation and route: The record mixes conventional, nano, phytosomal and other oral curcumin/curcuminoid formulations. Products, absorption enhancers, piperine combinations and other routes remain distinct; formulation equivalence is not established.
Dose: The original record describes trial-specific doses. Total product amounts, active amounts, frequency, adherence and direct dose response remain unverified; a single recommended or optimum dose is not generated.
Comparator: The retained comparator is placebo or control care. Placebo ingredients, lifestyle management, maintenance/changes of lipid or glucose medicines and added interventions remain incompletely verified. Combined effects are not assigned to curcumin alone or medicine replacement.
Measured outcome: The selected endpoint is blood LDL-C change. SMD and MD in mg/dL, final/change values, adjustment and measurement arrangements remain distinct. HDL, TG, total cholesterol and cardiovascular events address different questions.
Duration: The retained scope spans weeks to months across trials. Actual treatment, measurement, extraction, follow-up and post-discontinuation timepoints remain incompletely verified; these are not merged into a single fixed timepoint or persistent effect.
Questions outside this scope: The original D/30/Caution and B/S/R0/I2/E0/B2/C0 are retained. Historical cross-checking, independence and generic English verification wording are not inherited as current original-source reading or independent clinical validation.; R01 SMD −0.17, 95% CI −0.43 to 0.09, P=.20 and R02 MD −4.01 mg/dL, 95% CI −10.96 to 2.95, P=.259 are retained separately. Different scales, populations and formulations do not support conversion, addition or a new pooled estimate.; The original null interpretation is retained, while lack of significance does not establish no effect or equivalence for every formulation/population. Prespecified importance, direct comparisons, individual effects and clinical events remain separately unverified.; Roughly 6 to 10 mg/dL lower LDL in some earlier analyses is an original counterview narrative. Its original reports, denominators and intervals are unidentified; it is not assigned to the null R02 result or added as a separately verified report.; The narrative of meta-analysis comparisons from 2013 to 2025 and the 2022 bibliographies of the two structured citations are both retained. A new 2025 paper, completed current search or reconciled chronology is not invented.; Two review reports remain distinct from unique original trials, participants and independent teams. Original-trial counts, participant totals, overlap and contributing denominators remain unverified; reviews and samples are not summed or newly certified as independent replication.; Original gastrointestinal, bleeding and hepatobiliary precautions, and the caution against stopping lipid medicines without appropriate guidance, are retained. Actual harm collection, event counts, exposure/denominators, causality, interactions and long-term safety remain unverified.; The original evidence date 2026-09-08, correction of 2 English fields on 2026-09-14 and stored-summary production date 2026-10-06 remain distinct. Production timestamps are not completed external-reading/content-review dates; actual review dates remain unrecorded.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · 2022 · Updated curcumin and blood-lipid review across mixed diseases/formulations

PubMed

Material type: Stored description of a systematic review/meta-analysis of RCTs; external methods, searches and inclusion tables remain unread
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: SMD −0.17, 95% CI −0.43~0.09, P=.20
Record level: This is the stored standardized LDL difference from a mixed-disease/formulation review. Original analyses, denominators and timepoints remain unverified; it is not converted to mg/dL.
Study overlap and independent replication: The mixed-disease updated review and type 2 diabetes review remain distinct. Overlap and unique counts of original trials, additional reports and participants, and independent teams, remain unverified. Estimates on different scales are not converted or added, or established as two independent replications.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Existing stored summary acquired	Stored summary	Stored summary read	The stored report/citation summary was read. This does not record possession or full-text reading of the external original article. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
External abstract · Original PubMed link	Original bibliography link only; external content unread	Unread; no access attempt	Unread	Only the original PubMed URL is linked. Actual abstract reading, accessibility and bibliographic-content verification remain incomplete. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
External full text · Unacquired/unread	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original full texts, supplements, included trials and result tables remain unacquired/unread. Abstracts or summaries are not relabeled as full-text reading. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Review/original-trial registration material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Actual registration identifiers, contents, amendments and original-trial alignment remain unverified. Prespecification of articles/plans is not certified. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Protocols and statistical analysis plans	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original protocols, analysis plans, endpoint hierarchy, timepoints, multiplicity and attrition-handling rules remain unread. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.

R02 · 2022 · Curcumin, lipids and glycemic status review in type 2 diabetes

PubMed

Material type: Stored description of an RCT meta-analysis in type 2 diabetes; original trials, formulations and analyses remain unverified
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: MD −4.01 mg/dL, 95% CI −10.96 to 2.95, P=.259; described as null
Record level: This is the stored absolute LDL difference from a type 2 diabetes review. It remains distinct from another review's SMD and earlier positive narratives, and is not counted as an independent original trial.
Study overlap and independent replication: The mixed-disease updated review and type 2 diabetes review remain distinct. Overlap and unique counts of original trials, additional reports and participants, and independent teams, remain unverified. Estimates on different scales are not converted or added, or established as two independent replications.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Existing stored summary acquired	Stored summary	Stored summary read	The stored report/citation summary was read. This does not record possession or full-text reading of the external original article. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
External abstract · Original PubMed link	Original bibliography link only; external content unread	Unread; no access attempt	Unread	Only the original PubMed URL is linked. Actual abstract reading, accessibility and bibliographic-content verification remain incomplete. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
External full text · Unacquired/unread	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original full texts, supplements, included trials and result tables remain unacquired/unread. Abstracts or summaries are not relabeled as full-text reading. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Review/original-trial registration material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Actual registration identifiers, contents, amendments and original-trial alignment remain unverified. Prespecification of articles/plans is not certified. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.
Protocols and statistical analysis plans	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original protocols, analysis plans, endpoint hierarchy, timepoints, multiplicity and attrition-handling rules remain unread. Only stored summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread. URLs and original narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Original material-specific dates are retained. Stored-summary production timestamps on 2026-10-06 are not external-reading dates; dates for needed external material remain unrecorded. The original evidence date 2026-09-08 remains distinct from actual completed review.

Report counts versus independent study counts

The mixed-disease updated review and type 2 diabetes review remain distinct. Overlap and unique counts of original trials, additional reports and participants, and independent teams, remain unverified. Estimates on different scales are not converted or added, or established as two independent replications.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which LDL question is addressed?

Required materials and conditions: Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease
Conditions for verification: Original records on Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N02 · Are mixed formulations distinguished from individual products?

Required materials and conditions: Original-trial composition by conventional, nano and phytosomal formulations
Conditions for verification: Original records on Original-trial composition by conventional, nano and phytosomal formulations must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original-trial composition by conventional, nano and phytosomal formulations is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N03 · What doses and actual exposure are recorded?

Required materials and conditions: Total product and active-curcuminoid amounts, frequency and adherence
Conditions for verification: Original records on Total product and active-curcuminoid amounts, frequency and adherence must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Total product and active-curcuminoid amounts, frequency and adherence is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N04 · Are treatment duration and LDL measurement timepoints aligned?

Required materials and conditions: Trial-specific durations and LDL timepoints over weeks to months
Conditions for verification: Original records on Trial-specific durations and LDL timepoints over weeks to months must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific durations and LDL timepoints over weeks to months is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N05 · Which diagnoses make up the mixed adult population?

Required materials and conditions: Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL
Conditions for verification: Original records on Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N06 · How does the T2D analysis relate to the broader analysis?

Required materials and conditions: Alignment of T2D eligibility with mixed-disease and formulation scopes
Conditions for verification: Original records on Alignment of T2D eligibility with mixed-disease and formulation scopes must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Alignment of T2D eligibility with mixed-disease and formulation scopes is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N07 · How do comparator arrangements differ?

Required materials and conditions: Placebo or control care and common management in each group
Conditions for verification: Original records on Placebo or control care and common management in each group must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Placebo or control care and common management in each group is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N08 · Can lipid and glucose medicines be separated from other interventions?

Required materials and conditions: Group-specific lipid/glucose medicines, diet and weight changes
Conditions for verification: Original records on Group-specific lipid/glucose medicines, diet and weight changes must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Group-specific lipid/glucose medicines, diet and weight changes is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N09 · Are each review's design and eligibility scope retained separately?

Required materials and conditions: Search and eligibility criteria for the updated RCT review and T2D RCT review
Conditions for verification: Original records on Search and eligibility criteria for the updated RCT review and T2D RCT review must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Search and eligibility criteria for the updated RCT review and T2D RCT review is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N10 · Are the numbers of included trials known?

Required materials and conditions: Included RCT counts and study/report links for each review
Conditions for verification: Original records on Included RCT counts and study/report links for each review must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Included RCT counts and study/report links for each review is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N11 · Are participants and analysis denominators known?

Required materials and conditions: Trial/group denominators for allocation, analysis, completion and LDL measurement
Conditions for verification: Original records on Trial/group denominators for allocation, analysis, completion and LDL measurement must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial/group denominators for allocation, analysis, completion and LDL measurement is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N12 · Can trials shared by the reviews be linked?

Required materials and conditions: Review-to-original-trial, additional-report and shared-participant links
Conditions for verification: Original records on Review-to-original-trial, additional-report and shared-participant links must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Review-to-original-trial, additional-report and shared-participant links is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N13 · What is the LDL result in the broader updated analysis?

Required materials and conditions: R01 SMD, CI and P, with original model and scale
Conditions for verification: Original records on R01 SMD, CI and P, with original model and scale must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on R01 SMD, CI and P, with original model and scale is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N14 · What is the LDL result in the T2D analysis?

Required materials and conditions: R02 MD in mg/dL, CI and P, with the original analysis population
Conditions for verification: Original records on R02 MD in mg/dL, CI and P, with the original analysis population must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on R02 MD in mg/dL, CI and P, with the original analysis population is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N15 · Are SMD and MD in mg/dL kept without conversion?

Required materials and conditions: Units and estimands for standardized and absolute differences
Conditions for verification: Original records on Units and estimands for standardized and absolute differences must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Units and estimands for standardized and absolute differences is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N16 · Are intervals crossing no effect distinguished from equivalence?

Required materials and conditions: Both original CIs and P values, with prespecified importance/equivalence criteria
Conditions for verification: Original records on Both original CIs and P values, with prespecified importance/equivalence criteria must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Both original CIs and P values, with prespecified importance/equivalence criteria is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N17 · Which report underlies the roughly 6–10 mg/dL positive signal?

Required materials and conditions: Bibliography, formulations, denominators and CIs for earlier positive analyses
Conditions for verification: Original records on Bibliography, formulations, denominators and CIs for earlier positive analyses must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Bibliography, formulations, denominators and CIs for earlier positive analyses is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N18 · Are the 2013–2025 narrative and citation years distinguished?

Required materials and conditions: Review chronology, search end dates, versions and bibliography alignment
Conditions for verification: Original records on Review chronology, search end dates, versions and bibliography alignment must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Review chronology, search end dates, versions and bibliography alignment is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N19 · What explains differences and heterogeneity across analyses?

Required materials and conditions: Heterogeneity and sensitivity analyses by disease, formulation, duration and model
Conditions for verification: Original records on Heterogeneity and sensitivity analyses by disease, formulation, duration and model must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Heterogeneity and sensitivity analyses by disease, formulation, duration and model is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N20 · What is known about original-trial allocation, blinding and risk assessment?

Required materials and conditions: Original allocation, concealment, blinding/measurement methods and assessment bases
Conditions for verification: Original records on Original allocation, concealment, blinding/measurement methods and assessment bases must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original allocation, concealment, blinding/measurement methods and assessment bases is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N21 · Are LDL measurement, change and adjustment arrangements comparable?

Required materials and conditions: Assays, fasting, final/change values, baseline adjustment and estimands
Conditions for verification: Original records on Assays, fasting, final/change values, baseline adjustment and estimands must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Assays, fasting, final/change values, baseline adjustment and estimands is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N22 · What attrition, missingness and analysis exclusions are known?

Required materials and conditions: Trial-specific missing measurements, withdrawals and analysis sets
Conditions for verification: Original records on Trial-specific missing measurements, withdrawals and analysis sets must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Trial-specific missing measurements, withdrawals and analysis sets is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N23 · Are LDL prespecification and reporting choices verified?

Required materials and conditions: Primary/secondary endpoints, timepoints and multiplicity plans
Conditions for verification: Original records on Primary/secondary endpoints, timepoints and multiplicity plans must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Primary/secondary endpoints, timepoints and multiplicity plans is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N24 · Are disease/formulation subgroups kept separate from overall effects?

Required materials and conditions: Subgroup effects/CIs, denominators, prespecification and interactions
Conditions for verification: Original records on Subgroup effects/CIs, denominators, prespecification and interactions must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Subgroup effects/CIs, denominators, prespecification and interactions is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N25 · Are other lipid endpoints distinguished from LDL benefit?

Required materials and conditions: Outcome-specific definitions and results for HDL, TG and total cholesterol
Conditions for verification: Original records on Outcome-specific definitions and results for HDL, TG and total cholesterol must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Outcome-specific definitions and results for HDL, TG and total cholesterol is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N26 · Are statin replacement and myocardial-infarction prevention separate questions?

Required materials and conditions: Direct material distinguishing an LDL surrogate from medicine replacement and clinical events
Conditions for verification: Original records on Direct material distinguishing an LDL surrogate from medicine replacement and clinical events must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Direct material distinguishing an LDL surrogate from medicine replacement and clinical events is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N27 · Are replication within a formulation and optimum doses verified?

Required materials and conditions: Unique trials, independent teams and direct dose comparisons
Conditions for verification: Original records on Unique trials, independent teams and direct dose comparisons must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Unique trials, independent teams and direct dose comparisons is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N28 · Are four routes of company involvement distinguished?

Required materials and conditions: Report/trial-specific funding, product support, employee authorship and COI
Conditions for verification: Original records on Report/trial-specific funding, product support, employee authorship and COI must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Report/trial-specific funding, product support, employee authorship and COI is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N29 · Are harm collection methods and event tables known?

Required materials and conditions: Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events
Conditions for verification: Original records on Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N30 · Are harm denominators and exposure kept distinct?

Required materials and conditions: Safety populations, dosing, duration, event counts and comparators
Conditions for verification: Original records on Safety populations, dosing, duration, event counts and comparators must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Safety populations, dosing, duration, event counts and comparators is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N31 · Are alternative causes and concomitant treatments separated for harms?

Required materials and conditions: Comorbidities, medicines, event timing and alternative causes
Conditions for verification: Original records on Comorbidities, medicines, event timing and alternative causes must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Comorbidities, medicines, event timing and alternative causes is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N32 · Does a bleeding precaution establish a direct interaction result?

Required materials and conditions: Distinguishing a bleeding precaution from medicine-specific direct comparisons
Conditions for verification: Original records on Distinguishing a bleeding precaution from medicine-specific direct comparisons must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Distinguishing a bleeding precaution from medicine-specific direct comparisons is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N33 · Are long-term, hepatobiliary and vulnerable-population harms verified?

Required materials and conditions: Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure
Conditions for verification: Original records on Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N34 · Are stored-summary reading and external original links distinguished?

Required materials and conditions: Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs
Conditions for verification: Original records on Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N35 · How are generic English wording and the historical correction retained?

Required materials and conditions: Original Korean/English records and limits of the 2026-09-14 correction
Conditions for verification: Original records on Original Korean/English records and limits of the 2026-09-14 correction must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Original Korean/English records and limits of the 2026-09-14 correction is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

N36 · Are original grade, axes, dates and preparation distinguished?

Required materials and conditions: Preservation of D30, Caution, axes, evidence date and correction
Conditions for verification: Original records on Preservation of D30, Caution, axes, evidence date and correction must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Why this condition is needed: Material on Preservation of D30, Caution, axes, evidence date and correction is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-24 · Public page/material version 1.0

The public view and materials were prepared from the existing 36 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which LDL question is addressed?

Current findings: The original claim concerns LDL-C reduction in adults with dyslipidemia or metabolic disease. HDL, TG and total cholesterol are separate outcomes.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original eligibility criteria matching population, formulation, comparator and LDL are needed. Other lipids, myocardial infarction and medicine replacement are excluded.
Required materials and conditions: Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease
Materials to obtain first: Original eligibility criteria matching population, formulation, comparator and LDL are needed. Other lipids, myocardial infarction and medicine replacement are excluded.
Further research: Material needed: Original eligibility criteria matching population, formulation, comparator and LDL are needed. Other lipids, myocardial infarction and medicine replacement are excluded. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Oral curcumin and blood LDL-C change in adults with dyslipidemia or metabolic disease is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N02 · Are mixed formulations distinguished from individual products?

Current findings: The retained formulation mixes conventional, nano and phytosomal oral products. Other formulations, piperine combinations and topical products are not treated as equivalent.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Active amounts, absorption enhancers and product information are needed. A mixed estimate does not establish efficacy or equivalence for an individual formulation.
Required materials and conditions: Original-trial composition by conventional, nano and phytosomal formulations
Materials to obtain first: Active amounts, absorption enhancers and product information are needed. A mixed estimate does not establish efficacy or equivalence for an individual formulation.
Further research: Material needed: Active amounts, absorption enhancers and product information are needed. A mixed estimate does not establish efficacy or equivalence for an individual formulation. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original-trial composition by conventional, nano and phytosomal formulations must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original-trial composition by conventional, nano and phytosomal formulations is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N03 · What doses and actual exposure are recorded?

Current findings: Doses vary by trial. Representative doses, active-amount conversions and recommended amounts are not generated.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original trial records on formulation, dose, co-ingredients and adherence are needed.
Required materials and conditions: Total product and active-curcuminoid amounts, frequency and adherence
Materials to obtain first: Original trial records on formulation, dose, co-ingredients and adherence are needed.
Further research: Material needed: Original trial records on formulation, dose, co-ingredients and adherence are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Total product and active-curcuminoid amounts, frequency and adherence must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Total product and active-curcuminoid amounts, frequency and adherence is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N04 · Are treatment duration and LDL measurement timepoints aligned?

Current findings: The retained duration varies from weeks to months. It is not merged into a single fixed timepoint or persistent effect.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Treatment, measurement, end-of-follow-up and post-discontinuation timepoints, with selection rules, are needed.
Required materials and conditions: Trial-specific durations and LDL timepoints over weeks to months
Materials to obtain first: Treatment, measurement, end-of-follow-up and post-discontinuation timepoints, with selection rules, are needed.
Further research: Material needed: Treatment, measurement, end-of-follow-up and post-discontinuation timepoints, with selection rules, are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific durations and LDL timepoints over weeks to months must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific durations and LDL timepoints over weeks to months is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N05 · Which diagnoses make up the mixed adult population?

Current findings: The retained population mixes adults with these diagnoses. It is not presented as a single dyslipidemia population.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Inclusion tables by diagnosis, baseline LDL, age, comorbidities and eligibility are needed.
Required materials and conditions: Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL
Materials to obtain first: Inclusion tables by diagnosis, baseline LDL, age, comorbidities and eligibility are needed.
Further research: Material needed: Inclusion tables by diagnosis, baseline LDL, age, comorbidities and eligibility are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Dyslipidemia, T2D, metabolic syndrome and other diagnoses, with baseline LDL is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N06 · How does the T2D analysis relate to the broader analysis?

Current findings: R02 is a T2D RCT meta-analysis, while R01 mixes diseases and formulations. Two review reports are not counted as two independent original trials.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Alignment of diseases, formulations and timepoints, with original-trial lists shared by the reviews, is needed.
Required materials and conditions: Alignment of T2D eligibility with mixed-disease and formulation scopes
Materials to obtain first: Alignment of diseases, formulations and timepoints, with original-trial lists shared by the reviews, is needed.
Further research: Material needed: Alignment of diseases, formulations and timepoints, with original-trial lists shared by the reviews, is needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Alignment of T2D eligibility with mixed-disease and formulation scopes must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Alignment of T2D eligibility with mixed-disease and formulation scopes is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N07 · How do comparator arrangements differ?

Current findings: The retained comparator is placebo or control care. Identical placebo and lifestyle-management arrangements across all trials are not established.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original-trial records on comparator ingredients, blinding, diet/exercise management and added interventions are needed.
Required materials and conditions: Placebo or control care and common management in each group
Materials to obtain first: Original-trial records on comparator ingredients, blinding, diet/exercise management and added interventions are needed.
Further research: Material needed: Original-trial records on comparator ingredients, blinding, diet/exercise management and added interventions are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Placebo or control care and common management in each group must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Placebo or control care and common management in each group is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N08 · Can lipid and glucose medicines be separated from other interventions?

Current findings: The original precaution says not to stop lipid medicines without appropriate guidance. Medicine types, maintenance and changes in included trials are not detailed in the summary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Baseline medicines, treatment changes, adherence and shared care are needed. Curcumin alone or a statin-replacement comparison is not established.
Required materials and conditions: Group-specific lipid/glucose medicines, diet and weight changes
Materials to obtain first: Baseline medicines, treatment changes, adherence and shared care are needed. Curcumin alone or a statin-replacement comparison is not established.
Further research: Material needed: Baseline medicines, treatment changes, adherence and shared care are needed. Curcumin alone or a statin-replacement comparison is not established. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Group-specific lipid/glucose medicines, diet and weight changes must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Group-specific lipid/glucose medicines, diet and weight changes is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N09 · Are each review's design and eligibility scope retained separately?

Current findings: R01 is a systematic review/meta-analysis of RCTs; R02 is a T2D RCT meta-analysis. Disease and formulation scopes differ.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Search dates, strategies, eligibility, registration/plans and extraction tables are needed for each review. Currentness and directness are not newly certified.
Required materials and conditions: Search and eligibility criteria for the updated RCT review and T2D RCT review
Materials to obtain first: Search dates, strategies, eligibility, registration/plans and extraction tables are needed for each review. Currentness and directness are not newly certified.
Further research: Material needed: Search dates, strategies, eligibility, registration/plans and extraction tables are needed for each review. Currentness and directness are not newly certified. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Search and eligibility criteria for the updated RCT review and T2D RCT review must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Search and eligibility criteria for the updated RCT review and T2D RCT review is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N10 · Are the numbers of included trials known?

Current findings: R01 describes multiple RCTs with mixed diseases/formulations; R02 describes pooled T2D RCTs. Specific RCT counts are not provided.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Inclusion lists, multiple-arm arrangements and duplicate-report links are needed. Unique-trial counts are not generated.
Required materials and conditions: Included RCT counts and study/report links for each review
Materials to obtain first: Inclusion lists, multiple-arm arrangements and duplicate-report links are needed. Unique-trial counts are not generated.
Further research: Material needed: Inclusion lists, multiple-arm arrangements and duplicate-report links are needed. Unique-trial counts are not generated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Included RCT counts and study/report links for each review must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Included RCT counts and study/report links for each review is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N11 · Are participants and analysis denominators known?

Current findings: The stored sample descriptions contain no participant totals or group counts. Generic English wording does not supply actual denominators.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Allocation, analysis, completion and measurement denominators, with participant-overlap information, are needed. The final unique-participant total remains null.
Required materials and conditions: Trial/group denominators for allocation, analysis, completion and LDL measurement
Materials to obtain first: Allocation, analysis, completion and measurement denominators, with participant-overlap information, are needed. The final unique-participant total remains null.
Further research: Material needed: Allocation, analysis, completion and measurement denominators, with participant-overlap information, are needed. The final unique-participant total remains null. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial/group denominators for allocation, analysis, completion and LDL measurement must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial/group denominators for allocation, analysis, completion and LDL measurement is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N12 · Can trials shared by the reviews be linked?

Current findings: The two structured reports are the Saeedi and Yuan reviews. Overlap in original trials and participants remains unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Article, registration, site/time and sample links are needed. Review estimates are not added or certified as two independent replications.
Required materials and conditions: Review-to-original-trial, additional-report and shared-participant links
Materials to obtain first: Article, registration, site/time and sample links are needed. Review estimates are not added or certified as two independent replications.
Further research: Material needed: Article, registration, site/time and sample links are needed. Review estimates are not added or certified as two independent replications. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Review-to-original-trial, additional-report and shared-participant links must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Review-to-original-trial, additional-report and shared-participant links is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N13 · What is the LDL result in the broader updated analysis?

Current findings: R01 reports SMD −0.17, 95% CI −0.43 to 0.09, P=.20. Its retained interpretation describes the latest direct LDL synthesis as null.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original pooling tables, standardization, variances, weights, included-trial and timepoint extraction are needed. New values are not calculated.
Required materials and conditions: R01 SMD, CI and P, with original model and scale
Materials to obtain first: Original pooling tables, standardization, variances, weights, included-trial and timepoint extraction are needed. New values are not calculated.
Further research: Material needed: Original pooling tables, standardization, variances, weights, included-trial and timepoint extraction are needed. New values are not calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on R01 SMD, CI and P, with original model and scale must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on R01 SMD, CI and P, with original model and scale is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N14 · What is the LDL result in the T2D analysis?

Current findings: R02 reports MD −4.01 mg/dL, 95% CI −10.96 to 2.95, P=.259, described as null. R01's SMD is not copied to this report.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: T2D included trials, formulations, timepoints, variances/denominators and analysis models are needed.
Required materials and conditions: R02 MD in mg/dL, CI and P, with the original analysis population
Materials to obtain first: T2D included trials, formulations, timepoints, variances/denominators and analysis models are needed.
Further research: Material needed: T2D included trials, formulations, timepoints, variances/denominators and analysis models are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on R02 MD in mg/dL, CI and P, with the original analysis population must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on R02 MD in mg/dL, CI and P, with the original analysis population is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N15 · Are SMD and MD in mg/dL kept without conversion?

Current findings: R01 uses SMD; R02 uses MD in mg/dL. They are not compared, added or converted, and remain within their respective disease/formulation scopes.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original standard deviations, analysis arrangements and direct comparisons addressing the same question are needed. No SMD-to-mg/dL conversion or new pooled estimate is produced.
Required materials and conditions: Units and estimands for standardized and absolute differences
Materials to obtain first: Original standard deviations, analysis arrangements and direct comparisons addressing the same question are needed. No SMD-to-mg/dL conversion or new pooled estimate is produced.
Further research: Material needed: Original standard deviations, analysis arrangements and direct comparisons addressing the same question are needed. No SMD-to-mg/dL conversion or new pooled estimate is produced. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Units and estimands for standardized and absolute differences must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Units and estimands for standardized and absolute differences is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N16 · Are intervals crossing no effect distinguished from equivalence?

Current findings: The original CIs are −0.43 to 0.09 and −10.96 to 2.95. The original interpretation as null is retained.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original analysis tables and prespecified importance/equivalence criteria are needed. Lack of significance does not certify effect 0 or equivalence for every formulation.
Required materials and conditions: Both original CIs and P values, with prespecified importance/equivalence criteria
Materials to obtain first: Original analysis tables and prespecified importance/equivalence criteria are needed. Lack of significance does not certify effect 0 or equivalence for every formulation.
Further research: Material needed: Original analysis tables and prespecified importance/equivalence criteria are needed. Lack of significance does not certify effect 0 or equivalence for every formulation. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Both original CIs and P values, with prespecified importance/equivalence criteria must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Both original CIs and P values, with prespecified importance/equivalence criteria is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N17 · Which report underlies the roughly 6–10 mg/dL positive signal?

Current findings: The counterview mentions roughly 6–10 mg/dL lower LDL in some metabolic-disease analyses. Structured R02 instead reports −4.01 mg/dL, described as null. The positive narrative is not assigned to R02.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Articles/years, original trials and direct LDL tables for the positive analyses are needed. Unidentified reports, effects and CIs are not invented.
Required materials and conditions: Bibliography, formulations, denominators and CIs for earlier positive analyses
Materials to obtain first: Articles/years, original trials and direct LDL tables for the positive analyses are needed. Unidentified reports, effects and CIs are not invented.
Further research: Material needed: Articles/years, original trials and direct LDL tables for the positive analyses are needed. Unidentified reports, effects and CIs are not invented. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Bibliography, formulations, denominators and CIs for earlier positive analyses must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Bibliography, formulations, denominators and CIs for earlier positive analyses is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N18 · Are the 2013–2025 narrative and citation years distinguished?

Current findings: The research narrative mentions comparisons of meta-analyses from 2013–2025. Both structured citations have 2022 bibliographies. These different original records are retained.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Report lists, versions, search dates and original citations for the stated years are needed. No new 2025 paper or completed external current search is created.
Required materials and conditions: Review chronology, search end dates, versions and bibliography alignment
Materials to obtain first: Report lists, versions, search dates and original citations for the stated years are needed. No new 2025 paper or completed external current search is created.
Further research: Material needed: Report lists, versions, search dates and original citations for the stated years are needed. No new 2025 paper or completed external current search is created. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Review chronology, search end dates, versions and bibliography alignment must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Review chronology, search end dates, versions and bibliography alignment is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N19 · What explains differences and heterogeneity across analyses?

Current findings: The original narrative describes earlier positive/null findings and conclusions varying by disease/formulation. The result fields contain no I² value.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original heterogeneity, sensitivity/classification and extraction tables are needed. Different review scopes are not established as conflicting results from identical original trials; I² and prediction intervals are not invented.
Required materials and conditions: Heterogeneity and sensitivity analyses by disease, formulation, duration and model
Materials to obtain first: Original heterogeneity, sensitivity/classification and extraction tables are needed. Different review scopes are not established as conflicting results from identical original trials; I² and prediction intervals are not invented.
Further research: Material needed: Original heterogeneity, sensitivity/classification and extraction tables are needed. Different review scopes are not established as conflicting results from identical original trials; I² and prediction intervals are not invented. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Heterogeneity and sensitivity analyses by disease, formulation, duration and model must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Heterogeneity and sensitivity analyses by disease, formulation, duration and model is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N20 · What is known about original-trial allocation, blinding and risk assessment?

Current findings: The RCT-review design is retained. Original-trial methods and individual risk-assessment material were not externally read in this work.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original methods, registration/plans and review-level individual assessment bases are needed. Official RoB2/GRADE findings are not generated.
Required materials and conditions: Original allocation, concealment, blinding/measurement methods and assessment bases
Materials to obtain first: Original methods, registration/plans and review-level individual assessment bases are needed. Official RoB2/GRADE findings are not generated.
Further research: Material needed: Original methods, registration/plans and review-level individual assessment bases are needed. Official RoB2/GRADE findings are not generated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original allocation, concealment, blinding/measurement methods and assessment bases must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original allocation, concealment, blinding/measurement methods and assessment bases is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N21 · Are LDL measurement, change and adjustment arrangements comparable?

Current findings: The selected endpoint is blood LDL-C change. Original assays, final/change-value definitions and adjustment arrangements are not detailed in the summary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Assays, timepoints, extraction tables, variance handling and analysis plans are needed.
Required materials and conditions: Assays, fasting, final/change values, baseline adjustment and estimands
Materials to obtain first: Assays, timepoints, extraction tables, variance handling and analysis plans are needed.
Further research: Material needed: Assays, timepoints, extraction tables, variance handling and analysis plans are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Assays, fasting, final/change values, baseline adjustment and estimands must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Assays, fasting, final/change values, baseline adjustment and estimands is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N22 · What attrition, missingness and analysis exclusions are known?

Current findings: Stored sample descriptions provide no specific denominators. Unread original trials are not relabeled as having no missingness or withdrawals.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Group-specific flow diagrams, missingness, exclusion reasons, missing-data handling and sensitivity material are needed.
Required materials and conditions: Trial-specific missing measurements, withdrawals and analysis sets
Materials to obtain first: Group-specific flow diagrams, missingness, exclusion reasons, missing-data handling and sensitivity material are needed.
Further research: Material needed: Group-specific flow diagrams, missingness, exclusion reasons, missing-data handling and sensitivity material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Trial-specific missing measurements, withdrawals and analysis sets must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial-specific missing measurements, withdrawals and analysis sets is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N23 · Are LDL prespecification and reporting choices verified?

Current findings: An LDL-only verdict does not mean that every original trial prespecified LDL as its primary (1st) endpoint. Prespecified hierarchy remains unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Registration, protocols/SAPs and all-timepoint result tables are needed.
Required materials and conditions: Primary/secondary endpoints, timepoints and multiplicity plans
Materials to obtain first: Registration, protocols/SAPs and all-timepoint result tables are needed.
Further research: Material needed: Registration, protocols/SAPs and all-timepoint result tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Primary/secondary endpoints, timepoints and multiplicity plans must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Primary/secondary endpoints, timepoints and multiplicity plans is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N24 · Are disease/formulation subgroups kept separate from overall effects?

Current findings: The original rationale retains the latest direct null LDL result, while the counterview retains positive signals in restricted metabolic-disease analyses.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Subgroup tables, interactions and distinctions by formulation/duration are needed. The overall SMD is not copied as a disease-specific or product-specific estimate.
Required materials and conditions: Subgroup effects/CIs, denominators, prespecification and interactions
Materials to obtain first: Subgroup tables, interactions and distinctions by formulation/duration are needed. The overall SMD is not copied as a disease-specific or product-specific estimate.
Further research: Material needed: Subgroup tables, interactions and distinctions by formulation/duration are needed. The overall SMD is not copied as a disease-specific or product-specific estimate. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Subgroup effects/CIs, denominators, prespecification and interactions must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Subgroup effects/CIs, denominators, prespecification and interactions is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N25 · Are other lipid endpoints distinguished from LDL benefit?

Current findings: The summary states that these lipids are separate outcomes, and the rationale/advertising limits do not transfer positive TG or total-cholesterol findings to LDL.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original results for other lipids address separate questions. Effects and grades are not merged into the LDL table.
Required materials and conditions: Outcome-specific definitions and results for HDL, TG and total cholesterol
Materials to obtain first: Original results for other lipids address separate questions. Effects and grades are not merged into the LDL table.
Further research: Material needed: Original results for other lipids address separate questions. Effects and grades are not merged into the LDL table. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Outcome-specific definitions and results for HDL, TG and total cholesterol must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Outcome-specific definitions and results for HDL, TG and total cholesterol is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N26 · Are statin replacement and myocardial-infarction prevention separate questions?

Current findings: The retained advertising limits do not support statin replacement or myocardial-infarction prevention. The current endpoint is LDL-C.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Direct comparisons on medicine replacement or cardiovascular events are not verified in this material. Efficacy scope is not expanded.
Required materials and conditions: Direct material distinguishing an LDL surrogate from medicine replacement and clinical events
Materials to obtain first: Direct comparisons on medicine replacement or cardiovascular events are not verified in this material. Efficacy scope is not expanded.
Further research: Material needed: Direct comparisons on medicine replacement or cardiovascular events are not verified in this material. Efficacy scope is not expanded. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Direct material distinguishing an LDL surrogate from medicine replacement and clinical events must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Direct material distinguishing an LDL surrogate from medicine replacement and clinical events is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N27 · Are replication within a formulation and optimum doses verified?

Current findings: The original grading rationale describes conflicting syntheses and a null latest direct main effect. Mixed reviews do not establish formulation-specific replication or optimum doses.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Direct material on original-trial families, products, teams, doses and timepoints is needed.
Required materials and conditions: Unique trials, independent teams and direct dose comparisons
Materials to obtain first: Direct material on original-trial families, products, teams, doses and timepoints is needed.
Further research: Material needed: Direct material on original-trial families, products, teams, doses and timepoints is needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Unique trials, independent teams and direct dose comparisons must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Unique trials, independent teams and direct dose comparisons is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N28 · Are four routes of company involvement distinguished?

Current findings: R01 describes university researchers and mixed funding of included trials; R02 describes limited verification. Generic English funding wording does not complete these four records.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Original support, product-provision, affiliation and COI disclosures for reviews/trials are needed. University researchers do not establish absence of company involvement.
Required materials and conditions: Report/trial-specific funding, product support, employee authorship and COI
Materials to obtain first: Original support, product-provision, affiliation and COI disclosures for reviews/trials are needed. University researchers do not establish absence of company involvement.
Further research: Material needed: Original support, product-provision, affiliation and COI disclosures for reviews/trials are needed. University researchers do not establish absence of company involvement. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Report/trial-specific funding, product support, employee authorship and COI must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Report/trial-specific funding, product support, employee authorship and COI is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N29 · Are harm collection methods and event tables known?

Current findings: The original safety detail retains these precautions separately from efficacy. Collection methods and event tables are not preserved in detail.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Harm methods, severity, occurrence and discontinuation records are needed. Precautions do not establish incidence, causation or safety certification.
Required materials and conditions: Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events
Materials to obtain first: Harm methods, severity, occurrence and discontinuation records are needed. Precautions do not establish incidence, causation or safety certification.
Further research: Material needed: Harm methods, severity, occurrence and discontinuation records are needed. Precautions do not establish incidence, causation or safety certification. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Definitions, collection and discontinuation for gastrointestinal, bleeding and hepatobiliary events is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N30 · Are harm denominators and exposure kept distinct?

Current findings: Sample descriptions express review scopes without participant counts. Durations are mixed too.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Group-specific safety sets, exposure amounts/time, withdrawals and comparator events are needed. Harm incidence is not calculated or replaced with LDL denominators.
Required materials and conditions: Safety populations, dosing, duration, event counts and comparators
Materials to obtain first: Group-specific safety sets, exposure amounts/time, withdrawals and comparator events are needed. Harm incidence is not calculated or replaced with LDL denominators.
Further research: Material needed: Group-specific safety sets, exposure amounts/time, withdrawals and comparator events are needed. Harm incidence is not calculated or replaced with LDL denominators. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Safety populations, dosing, duration, event counts and comparators must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Safety populations, dosing, duration, event counts and comparators is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N31 · Are alternative causes and concomitant treatments separated for harms?

Current findings: The original record cautions against stopping lipid medicines without appropriate guidance and retains curcumin precautions separately. Event and co-treatment causation remains unverified.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Medicine maintenance/changes, baseline disease, event timing, comparators and post-discontinuation course are needed.
Required materials and conditions: Comorbidities, medicines, event timing and alternative causes
Materials to obtain first: Medicine maintenance/changes, baseline disease, event timing, comparators and post-discontinuation course are needed.
Further research: Material needed: Medicine maintenance/changes, baseline disease, event timing, comparators and post-discontinuation course are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Comorbidities, medicines, event timing and alternative causes must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Comorbidities, medicines, event timing and alternative causes is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N32 · Does a bleeding precaution establish a direct interaction result?

Current findings: A bleeding precaution is retained, but medicine-specific incidence and interaction comparisons are not specified. Medicine-specific causal claims are not added here.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Concomitant medicine types, exposure, group-specific events, alternative causes and direct comparisons are needed.
Required materials and conditions: Distinguishing a bleeding precaution from medicine-specific direct comparisons
Materials to obtain first: Concomitant medicine types, exposure, group-specific events, alternative causes and direct comparisons are needed.
Further research: Material needed: Concomitant medicine types, exposure, group-specific events, alternative causes and direct comparisons are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Distinguishing a bleeding precaution from medicine-specific direct comparisons must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing a bleeding precaution from medicine-specific direct comparisons is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N33 · Are long-term, hepatobiliary and vulnerable-population harms verified?

Current findings: Hepatobiliary precautions remain separate from efficacy. Mixed durations of weeks to months do not certify long-term safety.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Long-term follow-up, independent harm reports, vulnerable-population, exposure/denominator and causal material are needed. No new harm investigation is undertaken.
Required materials and conditions: Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure
Materials to obtain first: Long-term follow-up, independent harm reports, vulnerable-population, exposure/denominator and causal material are needed. No new harm investigation is undertaken.
Further research: Material needed: Long-term follow-up, independent harm reports, vulnerable-population, exposure/denominator and causal material are needed. No new harm investigation is undertaken. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Long-term/rare harms, hepatobiliary outcomes, vulnerable groups, independent reports and exposure is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N34 · Are stored-summary reading and external original links distinguished?

Current findings: The stored summary and bibliography were read. The two PubMed URLs are original links. External abstracts, full texts, registration and protocols/SAPs remain unread.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: Unread status remains until actual materials are acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions.
Required materials and conditions: Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs
Materials to obtain first: Unread status remains until actual materials are acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions.
Further research: Material needed: Unread status remains until actual materials are acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Access tables for stored reports, abstracts, full texts, registration and protocols/SAPs is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N35 · How are generic English wording and the historical correction retained?

Current findings: The correction records replacement of English placeholders while retaining grade, score, citations and evidence date. Remaining generic English denominator, result and funding wording is preserved in the original record.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: External English material and historical correction targets are not newly reviewed here. The historical correction is not labeled as completed current QA.
Required materials and conditions: Original Korean/English records and limits of the 2026-09-14 correction
Materials to obtain first: External English material and historical correction targets are not newly reviewed here. The historical correction is not labeled as completed current QA.
Further research: Material needed: External English material and historical correction targets are not newly reviewed here. The historical correction is not labeled as completed current QA. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Original Korean/English records and limits of the 2026-09-14 correction must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original Korean/English records and limits of the 2026-09-14 correction is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02

N36 · Are original grade, axes, dates and preparation distinguished?

Current findings: The original D/30/Caution, evidence date 2026-09-08, axes and correction are retained. This is not a new efficacy grade or independent verification.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliographies were read. External abstracts, full texts, registration, protocols/analysis plans, original trials, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Material gap: New material, changed conditions and changed verdicts are recorded as separate events after appropriate review. The original date is not reused as a current search or external-reading date.
Required materials and conditions: Preservation of D30, Caution, axes, evidence date and correction
Materials to obtain first: New material, changed conditions and changed verdicts are recorded as separate events after appropriate review. The original date is not reused as a current search or external-reading date.
Further research: Material needed: New material, changed conditions and changed verdicts are recorded as separate events after appropriate review. The original date is not reused as a current search or external-reading date. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in mixed formulations, diseases, doses, durations, analysis scales, timepoints, denominators, overlap, measurement, missingness, heterogeneity, support and harms. Original numbers, grades and independence narratives do not constitute new calculation, reassessment or clinical validation.
Conditions for verification: Original records on Preservation of D30, Caution, axes, evidence date and correction must link to reports, trials, denominators, formulations, diseases, LDL scales and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Preservation of D30, Caution, axes, evidence date and correction is needed to connect the relevant formulation, population, comparator, LDL scale/timepoint, report/trial, denominator, overlap or harm scope.
Application exceptions: Reviews with differing scopes, unique original trials and participants remain distinct, as do SMD and MD in mg/dL. Estimates are not added or converted, or extended to product/disease-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.
Referenced methods: Existing principles distinguish formulation, population, comparator, endpoint/scale, timepoint, reports/trials, denominators, overlap, support and harms in the retained LDL record.

Related sources R01 R02